s6y

Valneva SE

Ticker
VALN
CIK
1836564
Industry
Biological Products, (No Diagnostic Substances)

Ownership 7

  1. SC 13D/A Major Shareholders
  2. SC 13G/A Major Shareholders
  3. SC 13D/A Major Shareholders
  4. SC 13D Major Shareholders
  5. SC 13G Major Shareholders
  6. SC 13G Major Shareholders
  7. SC 13G Major Shareholders

Prospectus 11

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  5. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  6. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  7. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  8. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. DRSLTR Correspondence Related to Draft Registration Statement
  10. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

All 11 prospectus filings

Other 252

  1. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  2. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  3. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  4. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  5. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  6. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  7. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  8. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  9. EFFECT Notice of Effectiveness
  10. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

All 252 other filings